Drug Profile
Research programme: dermatology therapeutics - LEO Pharma/Fidelta
Latest Information Update: 06 Jan 2021
Price :
$50
*
At a glance
- Originator LEO Pharma
- Developer Fidelta; LEO Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 04 Jan 2021 Fidelta has been acquired by Selvita CRO SA
- 28 May 2018 No recent reports of development identified for research development in Skin-disorders in Croatia
- 28 May 2018 No recent reports of development identified for research development in Skin-disorders in Denmark